Lineage Cell Therapeutics has been granted a patent for compositions containing oligodendrocyte progenitor cells (OPCs) with specific markers for treating stroke, spinal cord injury, and multiple sclerosis. The container comprises OPCs expressing Nestin and other markers, with less than 15% undesirable cell types. GlobalData’s report on Lineage Cell Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Lineage Cell Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Lineage Cell Therapeutics, Embryonic stem cell culturing was a key innovation area identified from patents. Lineage Cell Therapeutics's grant share as of April 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Container with oligodendrocyte progenitor cells for treating neurological conditions

Source: United States Patent and Trademark Office (USPTO). Credit: Lineage Cell Therapeutics Inc

A recently granted patent (Publication Number: US11920155B2) discloses a container containing a composition comprising a population of cells, specifically oligodendrocyte progenitor cells (OPCs). These OPCs are derived from undifferentiated stem cells that were treated with specific stem cell differentiation modulating molecules before differentiation. The composition ensures that the population of cells contains less than 15% undesirable cell types, with a focus on OPCs expressing markers like Nestin, PDGF-Ra, IGF2, and others.

Furthermore, the patent details the characteristics of the undesirable cell types, particularly epithelial lineage cells, identified by markers like K7 and PCK. The container aims to maintain a low percentage of these undesirable cells, with specific claims stating less than 2% K7 positive cells and less than 5% PCK positive cells in the population. Additionally, the composition is specified to contain at least 1×106 cells per milliliter and have a volume ranging from 20 to 500 microliters, ensuring a concentrated and effective solution. The patent also emphasizes the high expression levels of markers like PDGF-Ra, NG2, and Nestin in the OPCs, with requirements of at least 95% expression for certain markers to meet the criteria outlined in the claims.

To know more about GlobalData’s detailed insights on Lineage Cell Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.